PMV Pharmaceuticals has appointed Salim Yazji to serve as chief medical officer of the Cranbury, NJ, cancer drug developer. Yazji most recently worked at Calimmune, where he was executive vice president and chief medical officer. Yazji will be based in the Boston area, where PMV is opening a site for its clinical and regulatory operations. Last year, PMV raised $74 million to advance into clinical trials testing a drug targeting tumor suppressor protein p53.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
